Compare Bristol-Myers Squibb Co (BMY) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Symbotic Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.63 (market cap $132.45B), while Symbotic Inc trades at $41.84 (market cap $5.21B). The key difference: Bristol-Myers Squibb Co is far larger — about 25.4× Symbotic Inc's market cap, and Bristol-Myers Squibb Co pays a 3.89% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| BMY | SYM | |
|---|---|---|
Market Cap | $132.45B | $5.21B |
Sector | Health | Technology |
52-Week High | $65.89 | $87.30 |
52-Week Low | $42.60 | $38.57 |
Enterprise Value | $166.44B | $3.46B |
Dividend Yield | 3.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SYM trades at $40.18, down 1.46% with bearish technical signals despite analyst optimism. Recent Q3 2026 earnings missed estimates at $0.09 vs. $0.13 expected, though revenue grew 21.7% year-over-year. The company shows weak profitability with a 0.31% net margin but maintains strong cash flow generation of $517 million in 2025. Technical indicators show bearish momentum with support at $39 and resistance at $42.
Outlook remains mixed with 61% analyst buy ratings and $60 consensus target suggesting 49% upside, but execution risks persist after recent earnings misses. Key catalysts include margin expansion and system deployments, while risks include competitive pressure and volatile earnings performance. The stock offers growth potential but requires careful monitoring of quarterly execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
